Sodium glucose co-transporter 2 inhibitors in the treatment of glomerular diseases: a CKJ controversy.

IF 3.9 2区医学 Q1 UROLOGY & NEPHROLOGY

Clinical Kidney Journal Pub Date : 2024-08-12 eCollection Date: 2024-09-01 DOI:10.1093/ckj/sfae237

Fernando Caravaca-Fontán, Lucia Del Vecchio, Manuel Praga, Jürgen Floege, Carmine Zoccali

引用次数: 0

Abstract

Integrating sodium-glucose co-transporter 2 inhibitors (SGLT2i) into the treatment for chronic kidney disease (CKD) has marked a significant therapeutic advance in nephrology. Clinical trials such as DAPA-CKD and EMPA-KIDNEY have demonstrated the beneficial effects of SGLT2i in slowing CKD progression and reducing proteinuria. However, the applicability of these results to patients with glomerulonephritis is still unresolved due to various limitations. This manuscript combines the evidence supporting the use of SGLT2i in glomerular diseases, highlights the limitations and strikes a conclusive balance on their role in clinical practice.

查看原文本刊更多论文

治疗肾小球疾病的葡萄糖钠协同转运体 2 抑制剂：CKJ 争议。

将钠-葡萄糖协同转运体 2 抑制剂（SGLT2i）纳入慢性肾脏病（CKD）的治疗中，标志着肾脏病学在治疗方面取得了重大进展。DAPA-CKD 和 EMPA-KIDNEY 等临床试验证明，SGLT2i 在延缓 CKD 病程进展和减少蛋白尿方面具有良好效果。然而，由于各种局限性，这些结果是否适用于肾小球肾炎患者的问题仍未得到解决。本手稿综合了支持在肾小球疾病中使用 SGLT2i 的证据，强调了其局限性，并就其在临床实践中的作用达成了结论性的平衡。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Kidney Journal Medicine-Transplantation

CiteScore

6.70

自引率

10.90%

发文量

242

审稿时长

8 weeks

期刊介绍： About the Journal Clinical Kidney Journal: Clinical and Translational Nephrology (ckj), an official journal of the ERA-EDTA (European Renal Association-European Dialysis and Transplant Association), is a fully open access, online only journal publishing bimonthly. The journal is an essential educational and training resource integrating clinical, translational and educational research into clinical practice. ckj aims to contribute to a translational research culture among nephrologists and kidney pathologists that helps close the gap between basic researchers and practicing clinicians and promote sorely needed innovation in the Nephrology field. All research articles in this journal have undergone peer review.